AC Immune First Half 2026 Financial and Corporate Update
AC Immune reported H1 2026 revenue of CHF 16.2 million, a seven-fold increase from the prior year, driven by milestone payments from partners Lilly and Takeda. The company narrowed its net loss to CHF 12.9 million and holds CHF 75.4 million in cash, which provides funding into Q4 2027. Near-term catalysts include H2 2026 data readouts for the wholly-owned ACI-7104 and ACI-19764 programs; Dr. Martin Zügel has succeeded Dr.
Key figures
- Revenue
- 16200000
- Cash position
- 75400000
- Goradia grant
- 4000000
- Lilly upfront
- 10000000
- Takeda milestone
- 12000000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.